

- oral, 236  
 pain, 1991  
 respiratory, 324  
 splenomegaly, 1992  
 thromboembolism, 739–740, 739f  
 clinical history, 1991–1992, 1992t  
 in cystic fibrosis, 367e–2, 1697  
 deaths from, by sex, 6e–1t  
 diagnosis of  
   algorithm for, 1994f  
   biopsy in, 1994. *See also* Liver biopsy  
   vs. DIC, 738  
   imaging in, 1993–1994, 1999  
   in jaundiced patient, 282–283  
   laboratory tests in, 1993, 1993t, 1999  
   liver function tests in. *See* Liver function tests  
 drug-induced, **2023**, 2056t  
   acetaminophen in, 43–44, 283, 366e–4f, 2025t, 2027, 2028f  
   amiodarone in, 2029  
   amoxicillin-clavulanate in, 2029  
   anabolic steroids in, 2029  
   antiretrovirals in, 2030  
   clinical features of, 2025t  
   erythromycin in, 2029  
   in exacerbation of preexisting liver disease, 1995  
   herbal medicines in, 2030  
   isoniazid in, 2025t, 2029  
   mechanisms of, 2023–2025, 2024f  
   nitrofurantoin in, 2029  
   oral contraceptives in, 2025t, 2029  
   parenteral nutrition in, 2030  
   phenytoin in, 2029  
   statins in, 2030  
   treatment of, 2025  
   trimethoprim-sulfamethoxazole, 2029–2030  
   in tuberculosis, 1117  
   valproate in, 2028  
 effect on drug concentration and response, 37  
 etiology of, 1990, 1990t  
 family history in, 1992  
 folate deficiency in, 647  
 genetic considerations in, 367e–1–2, 367e–1t, 1992, 2515, 2518  
 grading of, 1994–1995  
 granuloma, 367e–3, 2026t  
 in hemochromatosis, 367e–1–2, 367e–1t, 367e–2t, 2516, 2516f  
 in hepatitis. *See* Hepatitis  
 hepatocellular, 1990, 1990t  
 in HSCT recipients, 139e–3  
 in IBD, 1958  
 immunization recommendations for, 788f  
 infiltrative, 367e–1t, 367e–3  
 in leptospirosis, 1144  
 in lipid storage disorders, 367e–2–3  
 lymphoma, 367e–3  
 metabolic, 367e–1t, 367e–2–3  
 in NAFLD. *See* Nonalcoholic fatty liver disease (NAFLD)  
 obesity and, 415e–6  
 patterns of, 1990, 1990t  
 peripheral blood smear in, 81e–5f  
 physical examination in, 282–283, 1992–1993  
 in porphyrias, 367e–3  
 in pregnancy, 49  
 risk factors for, 1991–1992  
 in sarcoidosis, 2207–2208  
 in schistosomiasis, 1426  
 specialized nutritional support in, 98e–4  
 staging of, 1994–1995  
 thyroid hormone levels in, 2300  
 toxic, 2023, 2025t, 2026t  
 treatment of  
   liver transplantation. *See* Liver transplantation  
   stem cell therapy, 90e–3  
   tumors. *See* Liver tumors  
   in type 2 diabetes mellitus, 2405  
   in Wilson's disease, 1992, 2519  
   in women, 6e–1t  
 Liver flukes. *See* Biliary (hepatic) flukes  
 Liver function tests, **1995**  
   abnormal, evaluation of, 1993, 1994f, 1995, 1996f  
   blood ammonia, 1996  
   coagulation factors, 1998  
   serum albumin. *See* Albumin, serum  
   serum bilirubin. *See* Bilirubin, serum  
   serum enzymes, 1997. *See also* Alanine aminotransferase (ALT); Alkaline phosphatase (ALP); Aspartate aminotransferase (AST);  $\gamma$ -glutamyl transpeptidase (GGTP)  
   serum globulins, 1998  
   shortcomings of, 1995  
   urine bilirubin. *See* Bilirubin, urine  
   use of, 1998t, 1999  
 Liver pain, 1991  
 Liver phosphorylase deficiency (type VI GSD; Hers disease), 433e–2t, 433e–4  
 Liver phosphorylase kinase deficiency (type IX GSD), 433e–2t, 433e–4  
 LiverTox website, 2027  
 Liver transplantation, **2067**  
   for acute intermittent porphyria, 2529–2530  
   for alcoholic liver disease, 2053–2054, 2075  
   alternatives to, 2070–2071  
   for ATTR amyloidosis, 724  
   cadaver donor selection for, 2069–2070  
   candidate selection for, 2069–2070, 2069t  
   in children, 2068, 2068t  
   for cholangiocarcinoma, 553  
   complications of  
     anemia, 2072  
     graft rejection, 366e–3f, 2073  
     hepatic, 2072t, 2073  
     infections, 924t, 927–928, 1341f, 2072–2073  
     nonhepatic, 2072–2073, 2072t  
     recurrence of primary disease, 2068, 2073–2075  
     renal, 2072  
   contraindications to, 2068–2069, 2069t  
   for erythropoietic protoporphyria, 2533  
   frequency of, 2067  
   for hemochromatosis, 2518  
   for hepatocellular carcinoma, 549–550  
   history of, 2067  
   immunosuppressive therapy for, 2071–2072, 2764t, 2766t  
   indications for, 2067–2068, 2068t  
   living donor, 2070  
   MELD score and, 1995  
   for metastatic NETs, 575  
   for NALFD, 2057  
   orthotopic, 2067  
   outcome of, 2067, 2073  
   PELD system in, 1995  
   quality of life after, 2075  
   surgical technique for, 2070, 2070f  
   survival after, 2073  
   timing of, 2068  
 Liver tumors, **544**  
   benign, 553–554  
   cholangiocarcinoma. *See* Cholangiocarcinoma  
   epithelioid hemangioendothelioma, 552  
   hepatocellular carcinoma. *See* Hepatocellular carcinoma (HCC)  
   metastatic from other sites, 553  
 Liver X receptor, 2076  
 Living will, 58–59  
 LL3858, 205e–7  
 LLO (listeriolysin), 982  
 LMNA gene mutations, 94e–4, 435, 436t  
 LMO-2 gene, 91e–2  
 LMWH. *See* Low-molecular-weight heparin (LMWH)  
 LMX1B gene mutations, 1847  
 LMYC gene mutations, 101e–2t, 101e–3  
 Loading dose, 35, 35f  
 Loa loa (African eye worm)/loiasis  
   characteristics of parasite, 1418t, 1421  
   clinical features of, 1421, 1422f  
   diagnosis of, 245e–3t, 245e–6t, 765t, 1422  
   epidemiology of, 765t, 1418t, 1421  
   pathogenesis of, 1421  
   prophylaxis for, 1422  
   treatment of, 246e–8, 1422  
 Lobectomy, for lung cancer, 514, 516  
 Lobectomy, temporal, 2557  
 Lobeline, overdose/poisoning with, 473e–10t  
 Lobular neoplasia, 531–532  
 Local anesthetics, 242, 473e–13t  
 Local heat urticaria, 2118  
 Locked-in state, 41e–1v, 442e–2, 1771, 2578  
 Lockjaw (trismus), 985  
 Locus coeruleus, 465e–3, 465e–3f  
 Locus control region, 428  
 Locus (nonallelic) heterogeneity, 435–436, 436t, 447  
 Lod score, 442  
 Loeffler's syndrome, 422  
 Loeyes-Dietz syndrome, 1443, 1638, 1641, 2513  
 Lofexidine, 468e–3  
 Löffler's endocarditis, 1567  
 Löffler's syndrome, 1686–1687, 1686t  
 Löfgren's syndrome, 2206, 2207  
 LOH. *See* Loss of heterozygosity (LOH)  
 Lomitapide, 2448t, 2449  
 Lomustine (CCNU), 103e–9t, 601  
 Lone Star tick, 1160  
 Long-chain fatty acids/triglycerides, 1935, 1935t, 1936  
 Long-Distance Corridor Walk, 78t  
 Longevity. *See* Life expectancy  
 Longevity dividend, 94e–1  
 Long QT syndrome  
   arrhythmia in, 273e–4  
   clinical features of, 147, 1497  
   congenital, 41, 273e–4, 278e–12f, 1497  
   ECG in, 278e–12f, 1497f  
   genetic considerations in, 147, 1496t, 1497  
   genetic testing for, 450t  
   treatment of, 273e–4, 450, 450t  
 Long-term care, 83–84, 83t  
 Long terminal repeats (LTRs), 225e–1, 1218–1219, 1219f  
 Loop diuretics  
   action of, 299, 332e–4f, 332e–8  
   adverse effects of, 306  
   for chronic kidney disease, 1814, 1815  
   for hypercalcemia, 2480t  
   for hypercalcemia of malignancy, 610  
   for hyperkalemia, 312  
   for hypokalemia, 308  
   for hyponatremia, 302  
   for pulmonary edema, 1763  
 Loop of Henle  
   disorders involving, 332e–7t  
   embryologic development of, 332e–1–2  
   functions of, 332e–4f, 332e–8  
   in water absorption/excretion, 296, 296f  
 Looser's zones, 2466  
 Loperamide  
   for diarrhea, 103e–25, 267–268, 272  
   for irritable bowel syndrome, 1969, 1970t  
   for microscopic colitis, 270  
   for travelers' diarrhea, 797, 857t  
 Lopinavir, 1276f, 1278, 1280f  
 LOPS (loss of protective sensation), 2407  
 Lorazepam  
   for acute alcohol intoxication, 2727  
   for anxiety disorders, 2711t  
   for delirium, 64t, 65  
   for dyspnea, 62t  
   for insomnia, 65  
   for lumbar puncture analgesia, 443e–1  
   for nausea and vomiting, 62, 103e–25, 260t, 261  
   overdose/poisoning with, 473e–10t  
   pharmacology of, 2711t  
   for sedation after myocardial infarction, 1606  
   for status epilepticus, 1735, 2558f  
   during terminal weaning, 67  
 Lorcaserin, 2396–2397, 2397t, 2453  
 Lordotic posture, 462e–1, 462e–4f  
 Losartan  
   adverse effects of, 431e–5  
   genetic variations in response to, 39t, 40  
   for heart failure, 1512t